Bifidobacterium breve synergizes with Akkermansia muciniphila and Bacteroides ovatus to antagonize Clostridioides difficile
The ISME Journal · 02.01.2025 · 19 (1)
DOI: 10.1093/ismejo/wraf086 ↗Kurz gefasst
Fachartikel in der Zeitschrift The ISME Journal, online erschienen am 30.04.2025. Verfasst von Yanan Li und 7 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Microbial Technology, Nanjing Normal University, 2 Xuelin Road, Qixia District, Nanjing, Jiangsu 210033, China. Hauptthemen laut MEDLINE: Clostridioides difficile, Bifidobacterium breve, Clostridium Infections, Bacteroides. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
The development of ecologically based in vivo microecological formulations for treating Clostridioides difficile infection (CDI) is a current research focus. Here, we selected three microorganisms—Akkermansia muciniphila (AM), Bacteroides ovatus (BO), and Bifidobacterium breve (BB)—to formulate a mixed bacterial formulation (ABB). Subsequently, we evaluated the ecological interactions among these three microorganisms and investigated their therapeutic efficacy in a CDI murine model. Our investigation revealed the presence of a commensalism relationship among AM, BO, and BB. These microorganisms collectively formed a robust and densely packed symbiotic biofilm, with BB being the predominant member in terms of numerical abundance. This phenomenon was concomitant with a marked elevation in the levels of AI-2 and c-di-GMP. ABB exhibits the capability to inhibit crucial biological indicators of C. difficile (CD), such as toxin production, through the secretion of substantial quantities of lactic acid. Additionally, ABB indirectly suppresses CD by activating the NF-κB signaling pathway in Raw 264.7 cells, which stimulates the secretion of significant quantities of IL-6, IL-8, TNF-α, and IL-1β. ABB demonstrated exceptional efficacy in a CDI murine model, as evidenced by a substantial enhancement in survival rates and intestinal short-chain fatty acid level, the down-regulation of inflammation-associated cytokine secretion, a notable reduction in fecal CD toxin levels, and CD viable bacterial counts. Concurrently, there was an augmentation in the level of gut microbial diversity, accompanied by a rapid reduction in Enterococcus abundance. This ABB formulation holds promise for further development into a novel microecological formulation for the treatment of CDI.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- State Key Laboratory of Microbial Technology, Nanjing Normal University, 2 Xuelin Road, Qixia District, Nanjing, Jiangsu 210033, China.
- School of Food Science and Pharmaceutical Engineering, Nanjing Normal University, 2 Xuelin Road, Qixia District, Nanjing, Jiangsu 210033, China.
ORCID-Profile: Jingpeng Yang
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Li, Y., Rui, W., Sheng, X., Deng, X., Li, X., Meng, L., Huang, H., & Yang, J. (2025). Bifidobacterium breve synergizes with Akkermansia muciniphila and Bacteroides ovatus to antagonize Clostridioides difficile. The ISME Journal, 19(1). https://doi.org/10.1093/ismejo/wraf086
Vancouver
Li Y, Rui W, Sheng X, Deng X, Li X, Meng L, et al. Bifidobacterium breve synergizes with Akkermansia muciniphila and Bacteroides ovatus to antagonize Clostridioides difficile. The ISME Journal. 2025;19(1). doi:10.1093/ismejo/wraf086
BibTeX
@article{Li2025,
author = {Li, Yanan and Rui, Wen and Sheng, Xiaoya and Deng, Xilong and Li, Xiaoqian and Meng, Lingtong and Huang, He and Yang, Jingpeng},
title = {Bifidobacterium breve synergizes with Akkermansia muciniphila and Bacteroides ovatus to antagonize Clostridioides difficile},
journal = {The ISME Journal},
year = {2025},
volume = {19},
number = {1},
doi = {10.1093/ismejo/wraf086}
}
EUVIMED